Neurocrine Biosciences to Participate at Investor Conferences in September

Rhea-AI Summary

Neurocrine Biosciences (NBIX) has announced its participation in two major investor conferences this September. The company will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 4, 2024, at 3:20 p.m. ET, and the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024, at 8:45 a.m. ET.

Key executives, including CEO Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and CFO Matt Abernethy, will represent the company. Both presentations will be webcast live and accessible on Neurocrine's website, with replays available for approximately one month.

Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved treatments and a robust pipeline of compounds in clinical development.

News Market Reaction – NBIX

+3.77%

1 alert

+3.77% News Effect

On the day this news was published, NBIX gained 3.77%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Morgan Stanley 22^nd Annual Global Healthcare Conference on September 4 in New York

2024 Wells Fargo Healthcare Conference on September 5 in Boston

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at two upcoming investor conferences in September.

• Chief Executive Officer Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and Chief Financial Officer Matt Abernethy will present at the Morgan Stanley 22^nd Annual Global Healthcare Conference in New York at 3:20 p.m. Eastern Time on Wednesday, September 4, 2024.
• Kyle Gano and Matt Abernethy will present at the 2024 Wells Fargo Healthcare Conference in Boston at 8:45 a.m. Eastern Time on Thursday, September 5, 2024.

The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-september-302233393.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When and where is Neurocrine Biosciences (NBIX) presenting at investor conferences in September 2024?

Neurocrine Biosciences (NBIX) is presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 4, 2024, and the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024.

Who will be representing Neurocrine Biosciences (NBIX) at these investor conferences?

CEO Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and CFO Matt Abernethy will represent Neurocrine Biosciences (NBIX) at these investor conferences.

How can investors access Neurocrine Biosciences' (NBIX) presentations at the September 2024 conferences?

Investors can access live webcasts of Neurocrine Biosciences' (NBIX) presentations on the company's website under the Investors section at www.neurocrine.com. Replays will be available for approximately one month after the events.

What are the main therapeutic areas Neurocrine Biosciences (NBIX) focuses on?

Neurocrine Biosciences (NBIX) focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with FDA-approved treatments for conditions such as tardive dyskinesia, Huntington's disease chorea, endometriosis, and uterine fibroids.